日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

定量 HER2 组织和血浆分析可预测曲妥珠单抗 deruxtecan 对乳腺癌的活性。

Tarantino Paolo, Kim Se-Eun, Hughes Melissa E, Kusmick Ross J, Smith Kalie, Brasó-Maristany Fara, Nyein Chan Nay Nwe, Paré Brunet Laia, Alder Laura, Garcia-Cortes Diana, Gomez Tejeda Zanudo Jorge, Pereslete Alyssa M, Noteware Laura, Moore Heather, Van Swearingen Amanda E D, Li Tianyu, Gupta Hersh, D'Amico Olivia, Martini Alba, Morganti Stefania, Spindel Jennifer, Cook Charmaine, McLaughlin Christine, Dvir Kathrin, Garrido-Castro Ana C, Sammons Sarah, Files Janet, Sendrick Kerry, Buck Simone, Dillon Deborah, Jeselsohn Rinath, Li Yvonne Y, Cherniack Andrew D, LoRusso Patricia, Lustberg Maryam, Vega-León Rosario, Pardo Francisco, Davis Justin, Mueller Claudius, Corgiat Brian, Curigliano Giuseppe, Anders Carey K, Petricoin Emanuel F, Rimm David L, Prat Aleix, Tayob Nabihah, Lin Nancy U, Tolaney Sara M

Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer

HER2低表达转移性三阴性乳腺癌的雄激素受体表达和免疫特征

Tarantino, Paolo; Cha, Jaeyoon; Binboga Kurt, Busem; Chu, Xiangying; Jovanović, Bojana; Zhou, Andrew; Hughes, Melissa; Russo, Douglas; DiLullo, Molly; Wrabel, Eileen; Jeselsohn, Rinath; Lin, Nancy U; Carter, Jamie; Chen, Yisang Serenity; Li, Tianyu; Tayob, Nabihah; Mittendorf, Elizabeth A; Schnitt, Stuart J; Goel, Shom; Tolaney, Sara M

The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination.

CHI3L1-中性粒细胞轴驱动免疫抑制和乳腺癌转移扩散。

Taifour Tarek, Massé Adéline, Gu Yu, Sanguin-Gendreau Virginie, Zuo Dongmei, Xiao Bin, Solymoss Emilie, Shen Yunyun, Proud Hailey, Attalla Sherif Samer, Papavasiliou Vasilios, Lin Nancy U, Hughes Melissa E, Smith Kalie, Lee Chun Geun, Kamle Suchitra, Ursini-Siegel Josie, Elias Jack A, Siegel Peter M, Jeselsohn Rinath, Muller William J

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

阿贝西利联合氟维司群治疗CDK4/6抑制剂治疗进展后的晚期乳腺癌:MONARCH III期临床试验结果

Kalinsky, Kevin; Bianchini, Giampaolo; Hamilton, Erika; Graff, Stephanie L; Park, Kyong Hwa; Jeselsohn, Rinath; Demirci, Umut; Martin, Miguel; Layman, Rachel M; Hurvitz, Sara A; Sammons, Sarah; Kaufman, Peter A; Muñoz, Montserrat; Lai, Jiun-I; Knoderer, Holly; Sandoval, Cynthia; Chawla, Aarti R; Nguyen, Bastien; Zhou, Yanhong; Ravenberg, Elizabeth; Litchfield, Lacey M; Smyth, Lillian; Wander, Seth A

Tamoxifen induces PI3K activation in uterine cancer.

他莫昔芬可诱导子宫癌细胞中PI3K活化。

Kübler Kirsten, Nardone Agostina, Anand Shankara, Gurevich Daniel, Gao Jianjiong, Droog Marjolein, Hermida-Prado Francisco, Akhshi Tara, Feiglin Ariel, Feit Avery S, Cohen Feit Gabriella, Dackus Gwen, Pun Matthew, Kuang Yanan, Cha Justin, Miller Mendy, Gregoricchio Sebastian, Lanfermeijer Mirthe, Cornelissen Sten, Gibson William J, Paweletz Cloud P, Van Allen Eliezer M, van Leeuwen Flora E, Nederlof Petra M, Nguyen Quang-Dé, Mourits Marian J E, Radovich Milan, Leshchiner Ignaty, Stewart Chip, Matulonis Ursula A, Zwart Wilbert, Maruvka Yosef E, Getz Gad, Jeselsohn Rinath

Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

新辅助紫杉醇联合帕博利珠单抗治疗激素受体阳性乳腺癌的疗效、安全性及预测性生物标志物:一项随机试点试验

Waks, Adrienne G; Fu, Jingxin; Chu, Xiangying; Binboga Kurt, Busem; Li, Tianyu; Kuntz, Thomas M; Shen, Yizhuo; Yang, David; Meli, Kevin; Reardon, Brendan; Park, Jihye; Partridge, Ann; Abravanel, Daniel; Jeselsohn, Rinath; Wrabel, Eileen; Alberti, Jillian; DiLullo, Molly; Chen, Serenity; Mohammed-Abreu, Ayesha; Sun, Xiaopeng; Balko, Justin M; Kleijn, Miranda; Audeh, William; Morgan, Xochitl C; Krop, Ian E; Tayob, Nabihah; Van Allen, Eliezer M; Mittendorf, Elizabeth A; Tolaney, Sara M

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

作者更正:CDK7抑制剂samuraciclib I期研究中晚期乳腺癌患者的剂量递增和扩展队列

Coombes, R C; Howell, Sacha; Lord, Simon R; Kenny, Laura; Mansi, Janine; Mitri, Zahi; Palmieri, Carlo; Chap, Linnea I; Richards, Paul; Gradishar, William; Sardesai, Sagar; Melear, Jason; O'Shaughnessy, Joyce; Ward, Patrick; Chalasani, Pavani; Arkenau, Tobias; Baird, Richard D; Jeselsohn, Rinath; Ali, Simak; Clack, Glen; Bahl, Ashwani; McIntosh, Stuart; Krebs, Matthew G

Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer

早期原发性激素受体阳性乳腺癌抗PD-1和化疗期间的细胞重编程

Fu, Jingxin; Waks, Adrienne G; Pimenta, Erica; Titchen, Breanna; Bi, Kevin; Camp, Sabrina; Pappa, Theodora; Keenan, Tanya; Shannon, Erin; Vigneau, Sébastien; Bemus, Meredith; Nag, Anwesha; Thorner, Aaron R; Park, Jihye; DiLullo, Molly; Wrabel, Eileen; Jeselsohn, Rinath; Mittendorf, Elizabeth A; Abravanel, Daniel L; Tolaney, Sara M; Van Allen, Eliezer M

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

纳武利尤单抗联合低剂量伊匹木单抗治疗高突变 HER2 阴性转移性乳腺癌:一项 II 期试验 (NIMBUS)

Barroso-Sousa, Romualdo; Zanudo, Jorge Gomez Tejeda; Li, Tianyu; Reddy, Sangeetha M; Emens, Leisha A; Kuntz, Thomas M; Silva, Carolina Alves Costa; AlDubayan, Saud H; Chu, Hoyin; Overmoyer, Beth; Lange, Paulina; DiLullo, Molly K; Montesion, Meagan; Kasparian, Julie; Hughes, Melissa E; Attaya, Victoria; Basta, Ameer; Lin, Nancy U; Tayob, Nabihah; Jeselsohn, Rinath; Mittendorf, Elizabeth A; Tolaney, Sara M

Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer

联合抑制KAT6A/B和Menin可逆转乳腺癌中雌激素受体驱动的基因表达程序

Sarah Naomi Olsen,Bryn Anderson,Charlie Hatton,Zhengtao Chu,Christopher Simpkins,Yanhe Wen,Wallace Bourgeois,Elena L Haarer,Myles Brown,Rinath Jeselsohn,Alana L Welm,Eneda Toska,Scott A Armstrong